Lineage Cell Therapeutics Inc (AMEX: LCTX) kicked off on Tuesday, up 4.27% from the previous trading day, before settling in for the closing price of $1.17. Over the past 52 weeks, LCTX has traded in a range of $0.37-$1.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -2.93% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -111.11%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 43.20%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.02 earnings per share (EPS), higher than consensus estimate (set at -0.03) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -111.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.25% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Take a look at Lineage Cell Therapeutics Inc’s (LCTX) current performance indicators. Last quarter, stock had a quick ratio of 4.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.72 million. That was inferior than the volume of 1.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.02%.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 90.48%, which indicates a significant increase from 73.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0885 in the past 14 days, which was higher than the 0.0707 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0581, while its 200-day Moving Average is $0.6986. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $1.2667. Second resistance stands at $1.3133. The third major resistance level sits at $1.3767. If the price goes on to break the first support level at $1.1567, it is likely to go to the next support level at $1.0933. Assuming the price breaks the second support level, the third support level stands at $1.0467.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
The company with the Market Capitalisation of 278.60 million has total of 228,356K Shares Outstanding. Its annual sales at the moment are 9,500 K in contrast with the sum of -18,610 K annual income. Company’s last quarter sales were recorded 2,770 K and last quarter income was -30,460 K.
